🚀 VC round data is live in beta, check it out!
Getinge Valuation Multiples
Discover revenue and EBITDA valuation multiples for Getinge and similar public comparables like Bausch + Lomb, Caris Life Sciences, Bruker, Abbott India and more.
Getinge Overview
About Getinge
Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (35%), and life sciences (13%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales, Europe, Middle East, and Africa 35%, and Asia-Pacific the remaining 25%.
Founded
1904
HQ
Employees
11.8K
Website
Financials (LTM)
EV
$7B
Getinge Financials
Getinge reported last 12-month revenue of $4B and EBITDA of $727M.
In the same LTM period, Getinge generated $2B in gross profit, $727M in EBITDA, and $274M in net income.
Revenue (LTM)
Getinge P&L
In the most recent fiscal year, Getinge reported revenue of $4B and EBITDA of $718M.
Getinge expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4B | XXX | $4B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 48% | XXX | 46% | XXX | XXX | XXX |
| EBITDA | $727M | XXX | $718M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $274M | XXX | $256M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | — | — | $655M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Getinge Stock Performance
Getinge has current market cap of $6B, and enterprise value of $7B.
Market Cap Evolution
Getinge's stock price is $22.26.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7B | $6B | 0.3% | XXX | XXX | XXX | $0.94 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGetinge Valuation Multiples
Getinge trades at 1.8x EV/Revenue multiple, and 9.5x EV/EBITDA.
EV / Revenue (LTM)
Getinge Financial Valuation Multiples
As of April 20, 2026, Getinge has market cap of $6B and EV of $7B.
Equity research analysts estimate Getinge's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Getinge has a P/E ratio of 22.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 9.5x | XXX | 9.6x | XXX | XXX | XXX |
| EV/EBIT | 15.3x | XXX | 14.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3.7x | XXX | 3.8x | XXX | XXX | XXX |
| P/E | 22.2x | XXX | 23.7x | XXX | XXX | XXX |
| EV/FCF | 28.3x | XXX | 23.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Getinge Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Getinge Margins & Growth Rates
Getinge's revenue in the last 12 month declined by (0%).
Getinge's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Getinge's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Getinge's rule of X is 22% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Getinge Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (0%) | XXX | (3%) | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 22% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 17% | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 13% | XXX | 13% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 34% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Getinge Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Getinge | XXX | XXX | XXX | XXX | XXX | XXX |
| Bausch + Lomb | XXX | XXX | XXX | XXX | XXX | XXX |
| Caris Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Bruker | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Convatec Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Getinge M&A Activity
Getinge acquired XXX companies to date.
Last acquisition by Getinge was on XXXXXXXX, XXXXX. Getinge acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Getinge
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGetinge Investment Activity
Getinge invested in XXX companies to date.
Getinge made its latest investment on XXXXXXXX, XXXXX. Getinge invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Getinge
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Getinge
| When was Getinge founded? | Getinge was founded in 1904. |
| Where is Getinge headquartered? | Getinge is headquartered in Sweden. |
| How many employees does Getinge have? | As of today, Getinge has over 11K employees. |
| Who is the CEO of Getinge? | Getinge's CEO is Mattias Perjos. |
| Is Getinge publicly listed? | Yes, Getinge is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Getinge? | Getinge trades under GETI B ticker. |
| When did Getinge go public? | Getinge went public in 1998. |
| Who are competitors of Getinge? | Getinge main competitors are Bausch + Lomb, Caris Life Sciences, Bruker, Abbott India. |
| What is the current market cap of Getinge? | Getinge's current market cap is $6B. |
| What is the current revenue of Getinge? | Getinge's last 12 months revenue is $4B. |
| What is the current revenue growth of Getinge? | Getinge revenue growth (NTM/LTM) is (0%). |
| What is the current EV/Revenue multiple of Getinge? | Current revenue multiple of Getinge is 1.8x. |
| Is Getinge profitable? | Yes, Getinge is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Getinge? | Getinge's last 12 months EBITDA is $727M. |
| What is Getinge's EBITDA margin? | Getinge's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Getinge? | Current EBITDA multiple of Getinge is 9.5x. |
| What is the current FCF of Getinge? | Getinge's last 12 months FCF is $243M. |
| What is Getinge's FCF margin? | Getinge's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Getinge? | Current FCF multiple of Getinge is 28.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.